Read Online or Download The Cancer Market Outlook to PDF
Similar oncology books
The gastrointestinal music presents one of many exact platforms the place a number of malignancies, together with adenocarcinoma of the pancreas, esophagus and colon are every one linked to weight problems. This special organization is roofed during this quantity of power stability and melanoma from the epidemiologic, biologic and capability etiologic perspective.
With an annual fee of greater than 12 million worldwide diagnoses and seven. 6 million deaths, the societal and monetary burden of melanoma can't be overstated. mind metastases are the commonest malignant tumors of the principal frightened approach, but their prevalence seems to be expanding despite the development of melanoma cures.
This quantity develops effects on non-stop time branching methods and applies them to review expense of tumor progress, extending vintage paintings at the Luria-Delbruck distribution. in this case, the writer calculate the likelihood that mutations that confer resistance to remedy are current at detection and quantify the level of tumor heterogeneity.
- Clinical Oncology
- Esophageal Cancer – Cell and Molecular Biology, Biomarkers, Nutrition and Treatment
- Thyroid Cancer - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References
- Molecular Genetics of Cancer
- Oxford American Handbook of Oncology
Additional info for The Cancer Market Outlook to
Roche’s Xeloda (capecitabine) shows comparable efficacy rates to fluorouracil, but it is orally administered and treatment is cheaper. During the last half-decade a number of new agents, notably irinotecan (Pfizer) and oxaliplatin (Sanofi-Synthélabo), have entered the colorectal cancer market. These treatments are now used both alone and in combination with fluorouracil in the treatment of advanced colorectal cancer. Unmet needs Colorectal cancer presents a reasonable five-year overall survival rate of 61% (SEER Cancer Statistics 1998), but less than 10% of patients diagnosed with metastatic disease can expect to survive for five years.
There is also currently a need for consensus opinion on second-line treatments, and a need for increased randomized clinical trials to provide evidence for the various second-line approaches now in use. Furthermore, current hormonal treatments are expensive because of their long-term administration in prostate cancer, and there is a need for inexpensive, psychologically acceptable alternatives. Improvements in screening and diagnosis have led to increased early-stage diagnosis, but there remains a need for more expansive screening programs and increasing patient awareness, particularly in older men who are more at risk.
Traditionally this has been achieved by using an anti-androgen, but it is likely that many US urologists may now switch to Plenaxis. As such, Plenaxis may further reduce Lupron usage in prostate cancer. Third, the most immediate threat is expected from Zoladex (goserelin). After overtaking Lupron’s dominant position during in 2003, it will continue to eat into the older drug’s market share. The loss will become more pronounced on the expiry of Lupron’s patent in 2004, which will most likely result in more attractive pricing for Zoladex.